These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9615811)

  • 1. Melatonin as biological response modifier in cancer patients.
    Neri B; de Leonardis V; Gemelli MT; di Loro F; Mottola A; Ponchietti R; Raugei A; Cini G
    Anticancer Res; 1998; 18(2B):1329-32. PubMed ID: 9615811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of melatonin administration on cytokine production in patients with advanced solid tumors.
    Neri B; Brocchi A; Carossino A; Cinineri G; Gemelli M; Tommasi M; Cagnoni M
    Oncol Rep; 1995 Jan; 2(1):45-7. PubMed ID: 21597686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
    Lissoni P; Barni S; Tancini G; Brivio F; Tisi E; Zubelewicz B; Braczkowski R
    J Biol Regul Homeost Agents; 1994; 8(4):126-9. PubMed ID: 7660855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
    J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
    Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G
    Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P; Rovelli F; Meregalli S; Fumagalli L; Musco F; Brivio F; Brivio O; Esposti G
    J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
    Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni GJ
    J Biol Regul Homeost Agents; 1994; 8(3):77-80. PubMed ID: 7754792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for melatonin in supportive care?
    Lissoni P
    Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
    Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
    Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
    Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
    J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
    J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
    Lissoni P
    Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
    J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pineal gland as a central regulator of cytokine network.
    Lissoni P
    Neuro Endocrinol Lett; 1999; 20(6):343-349. PubMed ID: 11458197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppresses nocturnal melatonin production.
    Pontes GN; Cardoso EC; Carneiro-Sampaio MM; Markus RP
    J Pineal Res; 2007 Nov; 43(4):365-71. PubMed ID: 17910605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.